Who Qualifies for Wegovy Weight Loss Injections?

Choosing a suitable weight-management treatment depends on a person's body weight, medical history, and overall health. Prescription medication may be considered when lifestyle changes alone have not provided sufficient results or when excess weight is associated with health risks. Wegovy Injections in Dubai contain semaglutide, a medicine that helps regulate appetite and supports weight reduction in people who meet specific medical criteria. However, Wegovy is not intended for everyone who wants to lose a few kilograms. A healthcare professional must assess eligibility, review possible risks, and determine whether the treatment is appropriate.

Introduction

Wegovy is a prescription medication used for long-term weight management in eligible individuals. Its active ingredient, semaglutide, belongs to a group of medicines called GLP-1 receptor agonists. It works by influencing appetite-regulating signals, helping reduce hunger and increase feelings of fullness. The medication is generally prescribed alongside a reduced-calorie diet and increased physical activity. Eligibility depends on factors such as body mass index (BMI), existing weight-related health conditions, age, and medical history. A professional assessment is important because the same treatment may not be suitable for everyone.

BMI Requirements

Body mass index is one of the main measurements used to assess whether an adult may qualify for Wegovy. It is calculated using a person's weight in kilograms divided by their height in metres squared. Under the UAE product information, adults may be eligible if they have an initial BMI of 30 or higher, which falls within the obesity range. Adults with a BMI of 27 or higher but below 30 may also qualify if they have at least one weight-related medical condition. BMI is a screening tool rather than a complete measure of health, so healthcare professionals consider other factors before recommending treatment.

Weight-Related Conditions

People who are overweight and have certain medical conditions may qualify for Wegovy even if their BMI is below 30. These conditions can include high blood pressure, abnormal cholesterol levels, prediabetes, type 2 diabetes, obstructive sleep apnoea, or cardiovascular disease. Excess body weight can increase the risk of developing or worsening these conditions, making medically supervised weight management important. A healthcare professional may review medical records, blood pressure readings, blood glucose levels, and cholesterol results to understand the individual's health needs. Having one of these conditions does not automatically guarantee eligibility, as the full medical assessment remains essential.

Adult Candidates

Wegovy may be considered for adults who meet the approved BMI requirements and need additional support with weight management. It may be suitable for people who experience persistent hunger, difficulty controlling portions, or repeated challenges maintaining weight reduction. However, wanting to lose a small amount of weight for appearance-related reasons is not, by itself, an approved reason to use the medication. Healthcare professionals also consider whether the person can follow the recommended eating and activity plan and attend regular follow-up appointments. The decision should focus on medical suitability and potential health benefits rather than weight-loss expectations alone.

Adolescent Eligibility

Under the UAE product information, Wegovy may also be prescribed to adolescents aged 12 years and above who have obesity and weigh more than 60 kg. Obesity in this age group is assessed using age- and sex-specific BMI growth charts rather than the standard adult BMI cut-offs. Treatment requires careful medical supervision because adolescents are still growing and developing. Their nutritional needs, physical development, emotional wellbeing, and medical history must all be considered. The product information also recommends discontinuing and reassessing treatment if an adolescent has not achieved at least a 5% reduction in BMI after 12 weeks at the 2.4 mg or maximum tolerated dose.

Novo Nordisk Pro+1

Medical Assessment

Before prescribing Wegovy, a healthcare professional reviews several aspects of a person's health. This may include current weight, height, BMI, previous weight-management attempts, existing medical conditions, and medications. Depending on the individual's circumstances, blood pressure, blood glucose, cholesterol, kidney function, and other health indicators may also be assessed. The purpose is to determine whether the medication is appropriate and identify any factors that could increase the risk of side effects. Patients should provide accurate information about their medical history and discuss any previous reactions to weight-management medicines.

Previous Weight-Loss Attempts

A history of difficulty maintaining weight reduction may be relevant during an eligibility assessment. Some individuals follow structured eating plans and exercise regularly but continue to struggle with hunger, cravings, or weight regain. Others may have medical conditions or medications that influence body weight. Wegovy can provide additional support for eligible patients by helping regulate appetite and reduce calorie intake. However, previous unsuccessful attempts at weight loss do not automatically mean someone qualifies. The healthcare professional must still consider BMI, related health conditions, treatment risks, and the approved prescribing criteria.

Who Should Avoid It

Wegovy is not suitable for every individual. Under relevant prescribing guidance, it should not be used by people with a personal or family history of medullary thyroid carcinoma or those with multiple endocrine neoplasia syndrome type 2. It should also not be used for weight loss during pregnancy. People with a history of pancreatitis, gallbladder disease, severe digestive problems, or certain kidney conditions should discuss their medical history carefully with their prescriber. These conditions may require additional assessment or alternative treatment. Patients should never start the medication using another person's prescription or without professional guidance.

Medication Interactions

A healthcare professional should review all prescription medicines, over-the-counter products, and supplements before treatment begins. Wegovy is not recommended for use alongside other semaglutide-containing medicines or other GLP-1 receptor agonists. People with type 2 diabetes may need additional monitoring because semaglutide can affect blood glucose levels, particularly when combined with insulin or certain diabetes medicines. Patients should also tell their prescriber about medicines that may be affected by changes in stomach emptying. Sharing a complete medication list helps reduce avoidable risks and supports safer treatment decisions.

Treatment Process

For the commonly used Wegovy injection, treatment is administered once weekly under the skin of the abdomen, thigh, or upper arm. The starting dose is low and is gradually increased according to the prescribed schedule. This gradual approach helps the body adjust to semaglutide and may reduce digestive discomfort. Patients should receive instructions on using their specific injection device, choosing an injection site, and following the correct schedule. The dose should not be increased, reduced, or stopped without consulting the prescribing healthcare professional.

Lifestyle Requirements

Meeting the medical criteria for Wegovy does not mean that lifestyle changes are no longer necessary. The medication is intended to be used alongside a reduced-calorie eating plan and increased physical activity. A balanced diet should provide adequate protein, fibre, vitamins, minerals, and healthy fats. Suitable physical activities may include walking, swimming, cycling, and strength exercises, depending on individual ability. These habits support cardiovascular health, muscle strength, and general wellbeing while helping individuals work towards realistic weight-management goals.

Side Effects and Safety

Common side effects of Wegovy include nausea, vomiting, diarrhoea, constipation, abdominal discomfort, bloating, and indigestion. These symptoms may be more noticeable when treatment begins or the dose increases. More serious risks can include pancreatitis, gallbladder problems, dehydration-related kidney issues, and severe allergic reactions. The medication also carries a warning about thyroid C-cell tumours observed in animal studies, although the relevance of these findings to humans is not fully known. Patients should seek medical advice if they experience severe or persistent symptoms and discuss the complete safety information before starting treatment.

Regular Monitoring

Follow-up appointments help determine whether Wegovy is providing suitable benefits and whether any side effects need attention. Healthcare professionals may monitor weight changes, appetite, digestive symptoms, blood pressure, and blood glucose when relevant. They can also assess whether the current treatment plan remains appropriate or requires adjustment. Patients should report unexpected symptoms and avoid changing their dose independently. Regular monitoring is particularly important for people with diabetes or other existing medical conditions because weight-management treatment may affect their wider healthcare needs.

Conclusion

Wegovy may be suitable for adults with a BMI of 30 or higher, or adults with a BMI of 27 or higher who have at least one weight-related medical condition. Under the UAE product information, certain adolescents aged 12 and above with obesity and a body weight exceeding 60 kg may also qualify. However, BMI alone does not determine eligibility. Medical history, current medications, possible risks, and individual health needs must also be considered. A qualified healthcare professional can assess whether Wegovy is appropriate and recommend a safe weight-management plan.

Frequently Asked Questions

Can someone with a BMI below 30 qualify for Wegovy?

Yes. Adults with a BMI of 27 or higher but below 30 may qualify if they have at least one weight-related medical condition, such as high blood pressure, type 2 diabetes, or abnormal cholesterol levels.

Is Wegovy suitable for people who only want to lose a few kilograms?

Wegovy is a prescription medicine intended for people who meet specific medical eligibility criteria. It is not generally intended for individuals seeking minor cosmetic weight reduction without meeting those requirements.

Can teenagers use Wegovy?

Under the UAE product information, Wegovy may be prescribed to adolescents aged 12 years and above who have obesity and weigh more than 60 kg. Treatment requires specialist medical supervision and ongoing assessment.

Do people with type 2 diabetes qualify for Wegovy?

Some adults with type 2 diabetes may qualify if they meet the relevant BMI criteria. Their healthcare professional must review their blood glucose levels, current diabetes medicines, and overall health before prescribing it.

Can pregnant women use Wegovy?

No. Wegovy should not be used for weight loss during pregnancy. Anyone planning pregnancy or who becomes pregnant while taking the medication should contact their healthcare professional for advice.

Does everyone who meets the BMI criteria receive Wegovy?

No. Meeting the BMI requirements does not automatically guarantee a prescription. A healthcare professional must also assess medical history, current medications, possible contraindications, and individual treatment needs.

Is a medical consultation necessary before starting Wegovy?

Yes. Wegovy is a prescription medication and should only be started after a healthcare professional has assessed eligibility, explained potential side effects, and provided instructions for safe use.